Feedback (FDBK)

Sector:

Health Care

Index:

FTSE AIM All-Share

 20.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 140.00
  • 52 Week Low: 19.50
  • Currency: UK Pounds
  • Shares Issued: 13.33m
  • Volume: 4,973
  • Market Cap: £2.73m
  • RiskGrade: 267
  • Beta: 0.43

Feedback inks neighbourhood diagnostics collaboration deal

By Josh White

Date: Thursday 19 Sep 2024

LONDON (ShareCast) - (Sharecast News) - Medical imaging and diagnostic technology specialist Feedback announced a collaboration agreement with an unnamed provider of primary care solutions on Thursday, to develop a novel 'neighbourhood diagnostics solution' aimed at streamlining NHS diagnostic pathways and reducing patient wait times.
The AIM-traded firm said the proposed solution would integrate its 'Bleepa' technology with the partner's existing systems to improve the efficiency of diagnostic referrals between primary care, community diagnostic centres (CDCs), and secondary care facilities.

It said the approach was expected to enable certain diagnostic procedures to be conducted in community settings such as pharmacies or dedicated diagnostic facilities, increasing diagnostic capacity and supporting NHS efforts to reduce waitlist backlogs.

The collaboration would launch with a pilot programme designed to demonstrate the solution's effectiveness in reducing outpatient appointment requirements and optimising the GP referral process.

Initial discussions with potential customer sites were already in progress.

The board said the pilot aimed to showcase the platform's ability to reduce patient wait times, enhance the referral process, and scale efficiently across multiple GP practices.

If successful, the collaboration had the potential to significantly expand the reach of the Bleepa solution and create additional diagnostic capacity within the NHS.

The company estimated that over 190 million diagnostic tests per year could be redirected to community settings such as pharmacies, representing an estimated total addressable market of £382m annually.

There were also prospects for international expansion, depending on the outcomes of the pilot and subsequent commercial agreements.

"This collaboration aligns to the secretary of state's vision to move care out of traditional acute provider settings and into the community, closer to patients," said chief executive officer Dr Tom Oakley.

"If successful it will provide additional capacity to the NHS and help to overcome some of the difficulties being faced by CDCs, such as recruitment challenges, by enabling redirection to fully staffed facilities."

Dr Oakley said it would also offer patients the choice and the convenience of attending their local high street for routine NHS investigations, with what the company believed would be shorter wait times."

"Lord Darzi's paper, released on 12 September, calls directly for this solution.

"Given the impact that the combined product can deliver and the ability to leverage our partners existing footprint to scale the solution the company believes that we have a huge opportunity to support the new model of the NHS under the new Labour administration."

At 1142 BST, shares in Feedback were up 5.26% at 50p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Feedback Market Data

Currency UK Pounds
Share Price 20.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 140.00
52 Week Low 19.50
Volume 4,973
Shares Issued 13.33m
Market Cap £2.73m
Beta 0.43
RiskGrade 267

Feedback Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
22.85% above the market average22.85% above the market average22.85% above the market average22.85% above the market average22.85% above the market average
88.57% above the sector average88.57% above the sector average88.57% above the sector average88.57% above the sector average88.57% above the sector average
Price Trend
91.93% below the market average91.93% below the market average91.93% below the market average91.93% below the market average91.93% below the market average
89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average
Income Not Available
Growth
45.59% above the market average45.59% above the market average45.59% above the market average45.59% above the market average45.59% above the market average
77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average

What The Brokers Say

Strong Buy 0
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 1
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Feedback Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
11:22 9 @ 20.00p
11:21 9 @ 20.90p
08:12 4,955 @ 20.00p

Feedback Key Personnel

CEO Tom Oakley
CFO Anesh Patel

Top of Page